Spots Global Cancer Trial Database for Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Official Title: Neoadjuvant Chemotherapy Plus Camrelizumab in PD-L1-negative Locally Advanced Cervical Cancer: a Multicentre, Single-arm, Phase 2 Trial

Study ID: NCT06288360

Conditions

Cervical Cancer

Locally Advanced Cervical Cancer

PD-L1 Negative

Neoadjuvant Chemoimmunotherapy

Interventions

Study Description

Brief Summary: This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.

Detailed Description: This multicenter, prospective, single-arm clinical trial is designed to enroll patients with PD-L1-negative locally advanced cervical cancer with 1 course of priming neoadjuvant chemotherapy followed by 2 courses of neoadjuvant immunochemotherapy, to clarify the effects of neoadjuvant chemotherapy combined with a PD-1 inhibitor on tumor remission rate, surgical complications, and surgical cleanliness, and to evaluate the effects of neoadjuvant chemotherapy combined with a PD-1 inhibitor on the survival of patients with locally advanced cervical cancer, to clarify the effects of neoadjuvant chemotherapy combined with a PD-1 inhibitor on tumor remission rate, surgical complications, and complete resection rate, and to assess the effects of neoadjuvant chemotherapy combined with a PD-1 inhibitor on the survival of patients with locally advanced cervical cancer, and to explore the changes of local immune-related factors and tumor cells during the treatment process, as well as biomarkers that affect the efficacy of PD-1 combination therapy.